$34M Private Placement & FDA Clearance Secured By Therapeutics Company For Novel Cancer Treatment
Aprea Therapeutics Secures $34M in Private Placement Financing: A Major Step Forward in Oncology Research.
In a significant development in the field of precision oncology, Aprea Therapeutics, Inc. (NASDAQ: APRE) announced a private placement financing of up to $34 million. The financing is set to close around March 13, 2024, subject to customary closing conditions. The proceeds will be used to fund a Phase I clinical trial of APR-1051 and continue patient enrollment in an ongoing Phase I/IIa trial.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
